Updates are available Correction dated 2021-11-04
Click to view Correction: https://doi.org/10.1038/s41551-021-00828-4
-
Authors
Lee, Jung Seok https://orcid.org/0000-0002-9810-8647
Han, Patrick https://orcid.org/0000-0002-0370-0729
Chaudhury, Rabib
Khan, Shihan
Bickerton, Sean https://orcid.org/0000-0002-3514-0308
McHugh, Michael D.
Park, Hyun Bong
Siefert, Alyssa L.
Rea, Gerald
Carballido, José M. https://orcid.org/0000-0001-8465-0665
Horwitz, David A.
Criscione, Jason
Perica, Karlo
Samstein, Robert
Ragheb, Ragy
Kim, Dongin
Fahmy, Tarek M. https://orcid.org/0000-0001-8740-4179
- License Information
-
More Information
Article History
Received: 5 December 2019
Accepted: 4 August 2021
First Online: 6 October 2021
Change Date: 4 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-021-00828-4
Competing interests
: T.M.F is a founder and major shareholder of Toralgen Inc., which focuses on the use of the system described in this work for different disease states, including autoimmunity and specifically type 1 and type 2 diabetes.
